Background: Hypointense lesions on T1 weighted MRI, referred to as black holes (BH), are a marker of demyelination/axonal loss in multiple sclerosis (MS). There is some evidence that glatiramer acetate (GA) may decrease the conversion of new brain lesions to BH.
Methods: We used monthly 3 Tesla brain MRI scans for up to 2 years to study the development and evolution of new BH in 75 MS patients randomized to GA or Interferon β-1b (IFNb1b) in the BECOME study.
Findings: Of 1,224 newly enhancing lesions (NEL) appearing at baseline through 24 months in 61 patients, 767 (62•7%) showed an acute BH( ABH). The majority of ABH were transient and of similar duration by treatment group. Of 571 ABH in which MRI follow-up scans were available for ≥1 year, 103 (18.8%) were still visible ≥12 months after onset and were considered chronic BH (CBH). Only 12.1% of the 849 NEL with MRI follow-up ≥1 year converted to CBH, 9.8% with IFNβ1b and 15.2•% with GA (p=0•02). The conversion from ABH to CBH was also lower with IFNβ1b (15.2%) than with GA (21•4%), of borderline significance (p=0.06). The majority of patients who developed NEL did not develop CBH; however, about a quarter had conversion rates from ABH to CBH greater than 20%.
Interpretation: Only a minority of new brain lesions in MS patients treated with GA or IFNβ1b convert to CBH.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.